Happy Mother's Day! Taking A Look Ahead Watching and

New Post Public Reply Private Reply Replies (3) Message Board
MGK_2
676
Happy Mother's Day!

Taking A Look Ahead

Watching and waiting. Not just waiting, but also watching and stating what I see. Others too, who watch, as do I can see where we are headed.

Nader was put out, like unto death but not unto death. He had not been able to further himself regardless of the weapon he wielded. He had an inability to fight his foes. He was therefore shut down.

Early celebrations turned dark. The thinking that winning was imminent was hit with RTF and warning letters. Yet, Nader was right on both accounts and they pull ahead on their lies and deception.

Nader escapes by termination. His way out. CytoDyn's way out. Nader's steep monetary draw now eliminated. CytoDyn operates down to the bare minimum. Efficiency rules. We no longer barrel down head long the road with a megaphone announcing every detail and every play. Even the most prized and pertinent details are put away to be appropriately announced at strategic moments. However, what our enemies do not realize remains the same fact that the same power which Nader constantly orated and proclaimed about is the same power which will level them and it grows mightier by the day.

Things are not as it they may appear. Too many would love you to believe that CytoDyn is in dire straights. I believe CytoDyn will say something small about NASH 700 pretty soon. We already know that this will happen in mid-June, but I think we will get something prior to that. It doesn't have to be a complete revelation. It can be partial. Just need to keep them off our backs. We need them to have a taste of the bomb blast that's coming. Just give us a taste CytoDyn, we don't need to eat.

On Amarex, I stand by what I said yesterday. We won't negotiate. There is much behind the BLA they submitted to the FDA on our behalf for the HIV indication. There are perpetrators and big money as well as big pharma behind this act of maleficence. None are immune. All have deep pockets. All will be found out and discovered. The implications of which are enormous. CytoDyn swallows whole the elephant in the room. Negotiations? There will be nothing left to negotiate for, not even half an ear. No crumbs under the table. And Amarex will not be the only one consumed.

It seems like the waters are calm for big pharma's ship. It's smooth sailing right now. All they need to do is to continue to pay interest on the borrowed short shares and they will succeed on keeping the lid on leronlimab. Just, maintain at least the 50 million short shares, keeping the cork in the bottle and keep adding even more than 80% of daily trades as short. Do what ever it takes to keep this thing from blowing, even when the bottle is shaken, when the world wants in, and certainly, do what ever has to be done to keep this pressure cooker down. Therefore do it, they command to their brokers, short it, as long as the word Leronlimab is kept at bay.

CytoDyn shall speak and the bottle shakes. CytoDyn already know what they will say. That time soon approaches.

Sidley Austin shall speak. Their time comes, and is beyond the horizon.

Either one of these or the culmination of the two, but I think it will be sudden rather than a slow upward drip. A sudden spoken word, apt & apropos, brings on the sudden collapse of this tall stack of short suppressive shares and the elimination of any attack and the evaporation of the worst of them as CytoDyn will have engorged itself in their plunder.

That's my conclusion when it comes to Amarex and NASH.

//

Now onto partnerships.

Just to remind you all. I speak with confidence because we own Leronlimab. I have no other reason to be confident other than solely on account of our asset. I take my forwardness because of that drug.

Unless Amarex concludes rapidly and we are awarded a massive windfall, (which I do not perceive happening all that soon, but I know it will come), CytoDyn needs to partner. CytoDyn needs to remain in control of all the partnerships it engages into. The partner needs to understand that it is their privilege to partner with CytoDyn, because Leronlimab causes their drug to be successful. CytoDyn must maintain ownership of the molecule. All partnerships terminate once their drug goes generic. After that, doctors may prescribe their drug alone, Leronlimab alone or still the combination of the drug/the generic with Leronlimab.

Partnerships are the only way, without a massive windfall, to go forward. And that is why I think we need a CEO who already has experience with many big pharmaceuticals and who is respected by them. and who has pertinent contacts with them or he may know many of the pharmaceutical suppliers and supporters and be well credentialed. It will be through this person, that CytoDyn develops into a Big Pharma itself and within his tenure, that CytoDyn greatly expands and morphs into adulthood.

Obstacles? Road blocks? Detours? No. There won't be any.

Everyone will want to be paired up with Leronlimab and that is our opportunity to expand our indication list. Big Pharma's mantra will be, "If you can't beat 'em, join 'em." If you can't beat Leronlimab, then partner with it. CytoDyn decisively takes market share. Shorts will have found greener pastures for months and months already.

CytoDyn needs to remain vigilant. Be careful of the covenants you sign CytoDyn. Leronlimab may not be breached. That must be forbidden. There can be no access to its assembly or manufacturing. There can be no understanding to its formula. There can be no decoding.

If for whatever reason, this is actually breached. all contracts / partnerships cease at once and CytoDyn goes it alone again. That must be written in every contract. Whoever would have breached this will be fighting with their best foot forward to again destroy CytoDyn.



Hope we hear from CytoDyn shortly.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading

Top 5 Most Recently Viewed Articles

CRMLS Partners with Rayse to Enhance Agent-Client Transparency

Updated Category News Views 108

CRMLS Enhances Agent Value with Rayse Platform California Regional MLS (CRMLS), the leading multiple listing service in the nation, has made a significant move by integrating Rayse, a state-of-the-art agent value platform, into its offerings. This collaboration allows all CRMLS agent users to access Rayse at no cost directly through their MLS dashboard, marking a pivotal...

Continue Reading
UMG & TikTok's New Deal: A Boon for Artists?

Updated Category News Views 8

A New Era for Music Collaboration Universal Music Group and TikTok just cranked up the volume on their alliance, announcing a fresh, multi-year licensing agreement. This ain't just another handshake—it signals a seismic shift in how music gets discovered and consumed globally. Strengthened Bonds and Broadened Horizons Under this new agreement, TikTok will offer its...

Continue Reading
How an Investment in Thermo Fisher Scientific Transforms Wealth

Updated Category News Views 425

Unveiling the Growth of Thermo Fisher Scientific Investing is often seen as a pathway to wealth, and for those who placed their trust in Thermo Fisher Scientific Inc. (NYSE: TMO) two decades ago, the rewards have been substantial. This company, which specializes in scientific instrumentation, reagents, and consumables, has consistently outperformed the market. 20 Years of...

Continue Reading
European Energy A/S Launches Tender Offer for Green Bonds

Updated Category News Views 63

European Energy A/S Announces Its Tender Offer European Energy A/S has officially informed the market about a new opportunity for its bondholders. The company is targeting holders of its existing senior unsecured green bonds due in 2025 and 2026, inviting them to tender their bonds as part of a strategic financing move. Tender Offer Details Under this tender offer, which...

Continue Reading
Building a Rehabilitation Hospital: Encompass and BSA Join Forces

Updated Category News Views 170

Encompass Health and BSA Health System Join Forces Encompass Health Corp. and BSA Health System have embarked on a collaborative journey that aims to enhance rehabilitation services for patients recovering from various health challenges. This partnership marks a significant expansion in the healthcare landscape, focusing on providing dedicated rehabilitation care. A...

Continue Reading